Sign up to save your podcasts
Or
Share AI and Pharmacovigilance Under the FDA's New Emerging Drug Safety Technology Program
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
AI and Pharmacovigilance Under the FDA's New Emerging Drug Safety Technology Program
Join Troutman Pepper Partner Brett Mason for a podcast series analyzing the intersection of artificial intelligence (AI), health care, and the law.
In this installment of The Good Bot, host Brett Mason is joined by Partner Judy O'Grady and Associate Kyle Dolinsky to discuss the FDA’s new Emerging Drug Safety Technology Program (EDSTP) and how this program encourages the use of AI to improve the efficient collection, processing, and evaluation of single and aggregate patient safety data. They further discuss how the use of AI technologies is expected to reduce costs associated with pharmacovigilance in the future.
View all episodes
By Brett A. Mason, Brent T. Hoard, Erin S. Whaley, Troutman Pepper LockeJoin Troutman Pepper Partner Brett Mason for a podcast series analyzing the intersection of artificial intelligence (AI), health care, and the law.
In this installment of The Good Bot, host Brett Mason is joined by Partner Judy O'Grady and Associate Kyle Dolinsky to discuss the FDA’s new Emerging Drug Safety Technology Program (EDSTP) and how this program encourages the use of AI to improve the efficient collection, processing, and evaluation of single and aggregate patient safety data. They further discuss how the use of AI technologies is expected to reduce costs associated with pharmacovigilance in the future.